On the filings, McKesson (MCK) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
Cheap, cash-gushing drug-distribution utility compounding EPS via buybacks; a Med-Surg spinoff adds a catalyst at just its multiple.
Durable drug distributor compounding revenue ~9%/yr, but flat net income, razor-thin equity and a 34x GAAP P/E leave it fully priced.
| Metric | MCK | COR |
|---|---|---|
| Fundamentals score | 60 | 69 |
| Revenue growth (YoY) | +12.4% | +9.3% |
| Net income growth (YoY) | +44.5% | +3.0% |
| Net margin | 1.2% | 0.5% |
| Return on equity | — | 103.1% |
| ROIC (est.) | — | 22.6% |
| Liabilities / Equity | — | — |
| Piotroski F-score | 6 / 9 | 5 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 1, 2026, 9:38 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 12:06 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.